Image Source: Unsplash

An Introduction

This article highlights the 4 largest market cap clinical-stage psychedelic compound-based drug discovery companies in the munKNEE Psychedelic Compound Based Clinical-Stage Drug Stocks Portfolio with their stock performances MTD as of yesterday, in descending order, in the month of July, their areas of focus, and their latest news, analyses and commentary where available.

1.  Compass Pathways (CMPS): DOWN 8.1% MTD; UP 26.3% in July
   • focuses on the use of psilocybin (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
   • Latest news, analyses and commentary:
     • Compass Pathways announces second quarter 2024 financial results
2. GH Research (GHRS); DOWN 18.1% MTD; UP 6.3% in July
   • focuses on the use of mebufotenin, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine. Go here for much more extensive information on DMT.
   • Latest news, analyses and commentary: None
3. atai Life Sciences (ATAI): DOWN 21.3% MTD; UP 16.5% in July
   • focuses on the use of ketamine, DMT and ibogaine.  Go here for much more extensive information on Ketamine and here for much more extensive information on DMT.
   • Latest news, analyses and commentary:
     • atai Life Sciences Reports Second Quarter 2024 Financial Results
4. Mind Medicine (MNMD): DOWN 28.8% MTD; UP 28.4% in July
   • focuses on the use of LSD and MDMA. Go here for much more extensive information on LSD and here for much more extensive information on MDMA.
   • Latest news, analyses and commentary:
     • MindMed Reports Second Quarter 2024 Financial Results

Summary

On average, the above 4 stocks are DOWN 19.0% MTD after having gone UP 17.5% in July.

More By This Author:

 AI-Focused Drug Discovery Stocks Portfolio Hit Hard: Down 14% MTD
American Cannabis MSO Portfolio Bucked Trend: Up 4.6% Last Week
These 7 Semiconductor/AI-Related Portfolios Are Down 9%, On Average, So Far In August